# Novo says Wegovy injection lowers BMI and obesity rates in children in trial

- URL: https://talkfuse.com/story/novo-says-wegovy-injection-lowers-bmi-and-obesity-rates-in-children-in-trial/
- Published: 2026-11-16T15:00:01+00:00
- Updated: 2026-11-16T22:55:27+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/16/novo-wegovy-obesity-children-trial.html
- Topics: Business

## Key points

- Wegovy lowered BMI in a trial of children aged 6 to under 12.
- More than 40% of treated children no longer had obesity after 68 weeks.
- Long-term effects and treatment as children grow up remain uncertain.

## Summary

Novo Nordisk reported late-stage trial results showing that Wegovy substantially reduced BMI in children aged 6 to under 12 with obesity. The findings could help address a treatment gap for younger children, who currently have no approved obesity medicines, although the study does not show whether early treatment changes health outcomes over the long term.

The 167 participants also received dietary and physical activity support. After 68 weeks, BMI fell by 17.4% among children taking Wegovy and rose by 2.2% with placebo among those who stayed on treatment; across all participants, the estimated difference was 16.2 percentage points. More than 40% of treated children no longer met the definition of obesity, and Novo reported no growth or puberty-related safety concerns, but questions remain about treatment and maintenance as children grow up.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
